Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Safety of Inhaled LIQ861 in PAH
NCT03399604Phase 3Completed
- Sponsor
- Liquidia Corporation
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by Liquidia Corporation. Started Jan 2018; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03399604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399604.